Purpose

A pharmacokinetic (PK) study in patients with impaired hepatic function should be conducted in the following situations:

  • If hepatic metabolism and/or excretion accounts for substantial portion ( >20 percent of the absorbed drug) of the elimination of a parent drug or active metabolite;
  • In the case of a narrow therapeutic range drug, and;
  • If metabolism of the drug is unknown.

The design and conduct of these hepatic impairment (HI) studies may have evolved since the latest version of the relevant guidance document from the FDA (2003).

 

Access the Poster Here

Contact Us
Call Our Team 

Phone: +1 919 876 9300
Fax: +1 919 876 9360
Toll-Free: +1 866 462 7373

Authors

Ingrid Freije, Fadi Achkar, Mario Tanguay
Syneos Health Clinique, QC, Canada
Faculty of Pharmacy, Université de Montréal, QC, Canada